38 results on '"Scharpf, M."'
Search Results
2. Retirement Planning: How to Deal with Different Adjustment Trajectories?
- Author
-
Ertelt, B.-J. (ed.), Scharpf, M. (ed.), Froidevaux, A., Baumann, I., Maggiori, C., Wieber, F., Rossier, J., Ertelt, B.-J. (ed.), Scharpf, M. (ed.), Froidevaux, A., Baumann, I., Maggiori, C., Wieber, F., and Rossier, J.
- Abstract
In an aging society, the successful transition from work to retirement becomes a major challenge for individuals, organizations, and governments. This chapter aims to explore the relationship between retirement planning and adjustment, and the general assumption according to which planning for retirement leads to positive adjustment outcomes. To do so, first the different trajectories from employment to retirement in terms of well-being are described, and a synthesis of five distinct retiree types is proposed. We then focus on Schlossberg’s (2003) typology, according to which individuals combine several paths across time in retirement. Second, the chapter focuses on retirement planning as the first phase of the retirement process: Its antecedents (i.e., socio-economic, trait, motivational and socio-cognitive, and social variables) and consequences (i.e., financial security, health and well-being, subjective beliefs and expectations, and social life) are reviewed. Third, practical implications for career counselling interventions of retirement planning are proposed. They relate to the Transition to Retirement Questionnaire, identifying more vulnerable groups, and target four main ingredients that reinforce the positive impact of retirement planning on adjustment. Finally, future directions for research on the relationship between retirement planning and adjustment are suggested.
- Published
- 2017
3. Evidence for PTEN-independent Akt activation and Akt-independent p27Kip1 expression in advanced bladder cancer
- Author
-
MUNDHENK, J., primary, HENNENLOTTER, J., additional, ZUG, L., additional, ALLOUSSI, S.H., additional, TODENHOEFER, T., additional, GAKIS, G., additional, AUFDERKLAMM, S., additional, SCHARPF, M., additional, KUEHS, U., additional, STENZL, A., additional, and SCHWENTNER, C., additional
- Published
- 2011
- Full Text
- View/download PDF
4. Conifer Damage and Death Associated with the Use of Highway De-Icing Salt in the Lake Tahoe Basin of California and Nevada
- Author
-
R.F. Scharpf, M. Srago and R.F. Scharpf, M. Srago
- Published
- 1974
5. Retirement Planning: How to Deal with Different Adjustment Trajectories?
- Author
-
Froidevaux, Ariane, Baumann, Isabel, Maggiori, Christian, Wieber, Frank, Rossier, Jérôme, Ertelt, B.-J. (ed.), and Scharpf, M. (ed.)
- Subjects
Retirement planning ,331: Arbeitsökonomie ,305: Soziale Gruppen ,Retirement adjustment ,Older worker ,retirement process ,retirement planning ,retirement adjustment ,retirement trajectories ,retiree types ,career counselling ,Labor market - Abstract
In an aging society, the successful transition from work to retirement becomes a major challenge for individuals, organizations, and governments. This chapter aims to explore the relationship between retirement planning and adjustment, and the general assumption according to which planning for retirement leads to positive adjustment outcomes. To do so, first the different trajectories from employment to retirement in terms of well-being are described, and a synthesis of five distinct retiree types is proposed. We then focus on Schlossberg’s (2003) typology, according to which individuals combine several paths across time in retirement. Second, the chapter focuses on retirement planning as the first phase of the retirement process: Its antecedents (i.e., socio-economic, trait, motivational and socio-cognitive, and social variables) and consequences (i.e., financial security, health and well-being, subjective beliefs and expectations, and social life) are reviewed. Third, practical implications for career counselling interventions of retirement planning are proposed. They relate to the Transition to Retirement Questionnaire, identifying more vulnerable groups, and target four main ingredients that reinforce the positive impact of retirement planning on adjustment. Finally, future directions for research on the relationship between retirement planning and adjustment are suggested.
- Published
- 2017
6. Simulating Space Conditions Evokes Different DNA Damage Responses in Immature and Mature Cells of the Human Hematopoietic System.
- Author
-
Handwerk L, Schreier HK, Kraft D, Shreder K, Hemmersbach R, Hauslage J, Bonig H, Wiesmüller L, Fournier C, and Rall-Scharpf M
- Subjects
- Humans, DNA, Single-Stranded, DNA Breaks, Double-Stranded, DNA End-Joining Repair, DNA Damage, DNA Repair, Hematopoietic System
- Abstract
The impact of space radiation and microgravity on DNA damage responses has been discussed controversially, largely due to the variety of model systems engaged. Here, we performed side-by-side analyses of human hematopoietic stem/progenitor cells (HSPC) and peripheral blood lymphocytes (PBL) cultivated in a 2D clinostat to simulate microgravity before, during and after photon and particle irradiation. We demonstrate that simulated microgravity (SMG) accelerates the early phase of non-homologous end joining (NHEJ)-mediated repair of simple, X-ray-induced DNA double-strand breaks (DSBs) in PBL, while repair kinetics in HSPC remained unaltered. Repair acceleration was lost with increasing LET of ion exposures, which increases the complexity of DSBs, precluding NHEJ and requiring end resection for successful repair. Such cell-type specific effect of SMG on DSB repair was dependent on the NF-кB pathway pre-activated in PBL but not HSPC. Already under unperturbed growth conditions HSPC and PBL suffered from SMG-induced replication stress associated with accumulation of single-stranded DNA and DSBs, respectively. We conclude that in PBL, SMG-induced DSBs promote repair of radiation-induced damage in an adaptive-like response. HSPC feature SMG-induced single-stranded DNA and FANCD2 foci, i.e., markers of persistent replication stress and senescence that may contribute to a premature decline of the immune system in space.
- Published
- 2023
- Full Text
- View/download PDF
7. Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases.
- Author
-
Maas M, Kurcz A, Hennenlotter J, Scharpf M, Fend F, Walz S, Stühler V, Todenhöfer T, Stenzl A, Bedke J, and Rausch S
- Subjects
- Humans, Clinical Relevance, Kidney metabolism, Receptors, Chemokine metabolism, Biomarkers, Tumor metabolism, Receptors, CXCR4 genetics, Receptors, CXCR4 metabolism, Carcinoma, Renal Cell pathology, Kidney Neoplasms metabolism
- Abstract
C-X-C Motif Chemokine Receptor 4 (CXCR4) is part of the human chemokine system and involved in progression and metastasis in renal cell carcinoma (RCC). However, the role of CXCR4 protein expression in RCC remains controversial. In particular, data regarding the subcellular distribution of CXCR4 in RCC and RCC metastasis as well as CXCR4 expression in renal tumors of variant histology are limited. The aim of the present study was the evaluation of the differential CXCR4 expression in RCC primary tumor and metastatic tissue as well as in variant renal histologies. In addition, the prognostic capacity of CXCR4 expression in organ-confined clear cell RCC (ccRCC) was evaluated. Three independent renal tumor cohorts (primary ccRCC cohort n
1 = 64; cohort of various histological entities n2 = 146; metastatic RCC tissue cohort n3 = 92) were evaluated using tissue microarrays (TMA). After immunohistochemical staining for CXCR4, nuclear and cytoplasmic expression patterns were evaluated. CXCR4 expression was correlated with validated pathologic prognosticators, clinical data, and overall and cancer-specific survival. Positive cytoplasmic staining was observed in 98% of the benign and 38.9% of the malignant samples. Nuclear staining was positive for 94.1% of the benign samples and 83% of the malignant samples. The median cytoplasmic expression score was found to be higher in benign tissue than in ccRCC (130.00 vs. 0.00); median nuclear expression score analysis indicated the opposite (56.0 vs. 71.0). Within malignant subtypes, the highest expression score was seen in papillary renal cell carcinomas (cytoplasmic: 117.50, nuclear: 41.50). Within benign renal tumors, high cytoplasmic and nuclear CXCR4 expression scores were seen for oncocytomas (cytoplasmic: 100.00, nuclear: 31.00). Expression scores in RCC metastasis ranked between benign renal tissue and ccRCC in cytoplasmic and nuclear expression. Cytoplasmic CXCR4 expression was identified as a prognostic factor for OS and CSS ( p = 0.042; p = 0.019). Multivariate analysis including clinicopathological parameters did not reveal an independent prognostic character of CXCR4 expression. CXCR4 expression differs significantly within benign lesions and renal neoplasms. Cytoplasmic and nuclear expression of CXCR4 could be detected across all RCC subtypes. The prognostic value of CXCR4 in ccRCC was confirmed in univariate analysis.- Published
- 2023
- Full Text
- View/download PDF
8. Hybrid argon plasma coagulation (HybridAPC) versus sharp excision for the treatment of endometriosis: a prospective randomized clinical trial.
- Author
-
Keckstein JS, Keckstein S, Brunecker K, Neugebauer A, Nüssle D, Hoffmann S, Andress J, Neis F, Scharpf M, Enderle M, Rothmund R, Brucker SY, Jun MW, and Kraemer B
- Subjects
- Female, Humans, Argon Plasma Coagulation, Prospective Studies, Peritoneum pathology, Tissue Adhesions prevention & control, Tissue Adhesions surgery, Tissue Adhesions pathology, Endometriosis surgery, Endometriosis pathology, Laparoscopy methods
- Abstract
Purpose: Endometriosis is a benign, but potentially serious gynaecological condition in terms of abdominal pain and impaired fertility. Laparoscopic excision techniques are considered the therapeutic standard. HybridAPC is presented as a novel technique for the non-contact thermal ablation of peritoneal endometriosis with simultaneous protection of the underlying thermosensitive structures by creating a needle-free elevated fluid cushion which enables a safer exposure and distance, as well as potentially improved peritoneal conditioning prior to APC., Methods: In this prospective randomized clinical trial, 39 patients with 132 superficial endometriotic lesions in total were treated with HybridAPC or sharp excision in an initial laparoscopic procedure according to randomization. In a second-look laparoscopy, adhesion formation was rated macroscopically. Histologic samples were taken from previously treated areas for evaluation of eradication rate., Results: The eradication rate was not significantly different between HybridAPC treatment and sharp excision (65 vs. 81%, p = .55). Adhesions formed in 5% of HybridAPC-treated lesions and in 10% after sharp excision (p = .49). HybridAPC treatment was significantly faster than sharp excision (69 vs. 106 s, p < .05). No intra- and postoperative complications were registered., Conclusion: This clinical trial demonstrates the feasibility of this novel surgical technique with a promising impact on adhesion prevention. Compared to sharp excision, HybridAPC is likely to be a safe, tissue-preserving, and fast method for the treatment of peritoneal endometriosis., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
9. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
- Author
-
Büttner FA, Winter S, Stühler V, Rausch S, Hennenlotter J, Füssel S, Zastrow S, Meinhardt M, Toma M, Jerónimo C, Henrique R, Miranda-Gonçalves V, Kröger N, Ribback S, Hartmann A, Agaimy A, Stöhr C, Polifka I, Fend F, Scharpf M, Comperat E, Wasinger G, Moch H, Stenzl A, Gerlinger M, Bedke J, Schwab M, and Schaeffeler E
- Subjects
- B7-H1 Antigen, Humans, Immunotherapy, Prognosis, Sunitinib, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell genetics, Kidney Neoplasms drug therapy, Kidney Neoplasms genetics
- Abstract
Background: Renal cell carcinoma (RCC) is a heterogeneous disease comprising histologically defined subtypes. For therapy selection, precise subtype identification and individualized prognosis are mandatory, but currently limited. Our aim was to refine subtyping and outcome prediction across main subtypes, assuming that a tumor is composed of molecular features present in distinct pathological subtypes., Methods: Individual RCC samples were modeled as linear combination of the main subtypes (clear cell (ccRCC), papillary (pRCC), chromophobe (chRCC)) using computational gene expression deconvolution. The new molecular subtyping was compared with histological classification of RCC using the Cancer Genome Atlas (TCGA) cohort (n = 864; ccRCC: 512; pRCC: 287; chRCC: 65) as well as 92 independent histopathologically well-characterized RCC. Predicted continuous subtypes were correlated to cancer-specific survival (CSS) in the TCGA cohort and validated in 242 independent RCC. Association with treatment-related progression-free survival (PFS) was studied in the JAVELIN Renal 101 (n = 726) and IMmotion151 trials (n = 823). CSS and PFS were analyzed using the Kaplan-Meier and Cox regression analysis., Results: One hundred seventy-four signature genes enabled reference-free molecular classification of individual RCC. We unambiguously assign tumors to either ccRCC, pRCC, or chRCC and uncover molecularly heterogeneous tumors (e.g., with ccRCC and pRCC features), which are at risk of worse outcome. Assigned proportions of molecular subtype-features significantly correlated with CSS (ccRCC (P = 4.1E - 10), pRCC (P = 6.5E - 10), chRCC (P = 8.6E - 06)) in TCGA. Translation into a numerical RCC-R(isk) score enabled prognosis in TCGA (P = 9.5E - 11). Survival modeling based on the RCC-R score compared to pathological categories was significantly improved (P = 3.6E - 11). The RCC-R score was validated in univariate (P = 3.2E - 05; HR = 3.02, 95% CI: 1.8-5.08) and multivariate analyses including clinicopathological factors (P = 0.018; HR = 2.14, 95% CI: 1.14-4.04). Heterogeneous PD-L1-positive RCC determined by molecular subtyping showed increased PFS with checkpoint inhibition versus sunitinib in the JAVELIN Renal 101 (P = 3.3E - 04; HR = 0.52, 95% CI: 0.36 - 0.75) and IMmotion151 trials (P = 0.047; HR = 0.69, 95% CI: 0.48 - 1). The prediction of PFS significantly benefits from classification into heterogeneous and unambiguous subtypes in both cohorts (P = 0.013 and P = 0.032)., Conclusion: Switching from categorical to continuous subtype classification across most frequent RCC subtypes enables outcome prediction and fosters personalized treatment strategies., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
10. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
- Author
-
Reustle A, Menig LS, Leuthold P, Hofmann U, Stühler V, Schmees C, Becker M, Haag M, Klumpp V, Winter S, Büttner FA, Rausch S, Hennenlotter J, Fend F, Scharpf M, Stenzl A, Bedke J, Schwab M, and Schaeffeler E
- Subjects
- Deoxyglucose, Glucose, Glutamine, Humans, Niacinamide pharmacology, Tumor Microenvironment, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell metabolism, Kidney Neoplasms drug therapy, Kidney Neoplasms genetics, Kidney Neoplasms metabolism
- Abstract
Background: The metabolic enzyme nicotinamide-N-methyltransferase (NNMT) is highly expressed in various cancer entities, suggesting tumour-promoting functions. We systematically investigated NNMT expression and its metabolic interactions in clear cell renal cell carcinoma (ccRCC), a prominent RCC subtype with metabolic alterations, to elucidate its role as a drug target., Methods: NNMT expression was assessed in primary ccRCC (n = 134), non-tumour tissue and ccRCC-derived metastases (n = 145) by microarray analysis and/or immunohistochemistry. Findings were validated in The Cancer Genome Atlas (kidney renal clear cell carcinoma [KIRC], n = 452) and by single-cell analysis. Expression was correlated with clinicopathological data and survival. Metabolic alterations in NNMT-depleted cells were assessed by nontargeted/targeted metabolomics and extracellular flux analysis. The NNMT inhibitor (NNMTi) alone and in combination with the inhibitor 2-deoxy-D-glucose for glycolysis and BPTES (bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl-sulfide) for glutamine metabolism was investigated in RCC cell lines (786-O, A498) and in two 2D ccRCC-derived primary cultures and three 3D ccRCC air-liquid interface models., Results: NNMT protein was overexpressed in primary ccRCC (p = 1.32 × 10
-16 ) and ccRCC-derived metastases (p = 3.92 × 10-20 ), irrespective of metastatic location, versus non-tumour tissue. Single-cell data showed predominant NNMT expression in ccRCC and not in the tumour microenvironment. High NNMT expression in primary ccRCC correlated with worse survival in independent cohorts (primary RCC-hazard ratio [HR] = 4.3, 95% confidence interval [CI]: 1.5-12.4; KIRC-HR = 3.3, 95% CI: 2.0-5.4). NNMT depletion leads to intracellular glutamine accumulation, with negative effects on mitochondrial function and cell survival, while not affecting glycolysis or glutathione metabolism. At the gene level, NNMT-depleted cells upregulate glycolysis, oxidative phosphorylation and apoptosis pathways. NNMTi alone or in combination with 2-deoxy-D-glucose and BPTES resulted in inhibition of cell viability in ccRCC cell lines and primary tumour and metastasis-derived models. In two out of three patient-derived ccRCC air-liquid interface models, NNMTi treatment induced cytotoxicity., Conclusions: Since efficient glutamine utilisation, which is essential for ccRCC tumours, depends on NNMT, small-molecule NNMT inhibitors provide a novel therapeutic strategy for ccRCC and act as sensitizers for combination therapies., (© 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.)- Published
- 2022
- Full Text
- View/download PDF
11. Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma.
- Author
-
Sauter-Meyerhoff C, Bohnert R, Mazzola P, Stühler V, Kandabarau S, Büttner FA, Winter S, Herrmann L, Rausch S, Hennenlotter J, Fend F, Scharpf M, Stenzl A, Ossowski S, Bedke J, Schwab M, and Schaeffeler E
- Abstract
Metastatic renal cell carcinoma (RCC) exhibits poor prognosis. Better knowledge of distant metastases is crucial to foster personalized treatment strategies. Here, we aimed to investigate the genetic landscape of metastases, including synchronous and/or recurrent metastases to elucidate potential drug target genes and clinically relevant mutations in a real-world setting of patients. We assessed 81 metastases from 56 RCC patients, including synchronous and/or recurrent metastases of 19 patients. Samples were analysed through next-generation sequencing with a high coverage (~1000× mean coverage). We therefore established a novel sequencing panel comprising 32 genes with impact on RCC development. We observed a high frequency of mutations in known RCC driver genes (e.g., >40% carriers of VHL and PBRM1 mutations) in metastases irrespective of the metastatic site. The somatic mutational composition was significantly associated with cancer-specific survival ( p (logrank) = 0.03). Moreover, we identified in 34 patients at least one drug target gene as well as clinically relevant mutations listed in the VICC Meta-Knowledgebase in 7%. In addition to significantly higher mutational burden in recurrent metastases compared to earlier ones, synchronous and/or recurrent metastases of individual patients, even after a time-period >2 yrs, shared a high proportion of somatic events. Our data demonstrate the importance of somatic profiling in metastases for precision medicine in RCC.
- Published
- 2021
- Full Text
- View/download PDF
12. p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics.
- Author
-
Diesing K, Ribback S, Winter S, Gellert M, Oster AM, Stühler V, Gläser E, Adler F, Hartwig C, Scharpf M, Bedke J, Burchardt M, Schwab M, Lillig CH, and Kroeger N
- Subjects
- Carcinoma, Renal Cell genetics, Female, Humans, Kidney Neoplasms genetics, Male, Mutation, Transcriptome, Tumor Suppressor Protein p53 genetics, Carcinoma, Renal Cell metabolism, Kidney Neoplasms metabolism, Tumor Suppressor Protein p53 metabolism
- Abstract
Purpose: Although p53 is rarely mutated in ccRCC, its overexpression has been linked to poor prognosis. The current study sought to elucidate the unique role of p53 in ccRCC with genomic, proteomic, and functional analyses., Materials and Methods: Data from the Cancer Genome Atlas (TCGA) were evaluated for genomic and proteomic characteristics of p53; a tissue micro array (TMA) study was carried out to evaluate the association of p53 and phosphorylated p53 (pp53) with clinical outcome. Mechanistic in vitro experiments were performed to confirm a pro-apoptotic loss of p53 in ccRCC and p53 isoforms as well as posttranslational modifications of p53 where assessed to provide possible reasons for a functional inhibition of p53 in ccRCC., Results: A low somatic mutation rate of p53 could be confirmed. Although mRNA levels were correlated with poor prognosis and clinicopathological features, there was no monotonous association of mRNA levels with survival outcome. Higher p53 protein levels could be confirmed as poor prognostic features. In vitro, irradiation of ccRCC cell lines markedly induced levels of p53 and of activated (phosphorylated) p53. However, irradiated ccRCC cells demonstrated similar proliferation, migration, and p53 transcriptional activity like non-irradiated controls indicating a functional inhibition of p53. p53 isoforms and could not be correlated with clinical outcome of ccRCC patients., Conclusions: p53 is rarely mutated but the wildtype p53 is functionally inhibited in ccRCC. To investigate mechanisms that underlie functional inhibition of p53 may provide attractive therapeutic targets in ccRCC., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
13. Hypofractionated preoperative radiotherapy for high risk soft tissue sarcomas in a geriatric patient population.
- Author
-
Potkrajcic V, Traub F, Hermes B, Scharpf M, Kolbenschlag J, Zips D, Paulsen F, and Eckert F
- Subjects
- Aged, Feasibility Studies, Humans, Recurrence, Retrospective Studies, Sarcoma radiotherapy, Sarcoma surgery, Soft Tissue Neoplasms radiotherapy, Soft Tissue Neoplasms surgery
- Abstract
Background: Standard therapy for localised, resectable high risk soft tissue sarcomas consists of wide excision and radiotherapy over several weeks. This treatment schedule is hardly feasible in geriatric and frail patients. In order not to withhold radiotherapy from these patients, hypofractionated radiotherapy with 25 Gy in 5 fractions was evaluated in a geriatric patient population., Patients and Methods: A retrospective analysis was performed of 18 geriatric patients with resectable high risk soft tissue sarcomas of extremities and thoracic wall. Wound healing and short term oncologic outcome were analysed. In addition, dose constraints for radiotherapy of the extremities were transferred from normofractionated to hypofractionated radiotherapy regimens., Results: Feasibility was good with 17/18 patients completing treatment as planned. Wound healing complication rate was in the range of published data. Two patients developed local and distant recurrence, two patients isolated distant recurrences. No isolated local recurrences were observed. Keeping the constraints was possible in all cases without compromising the coverage of the target volume., Conclusions: Hypofractionated radiotherapy and surgery was well tolerated even in this specific patient population. With feasibility concerning early wound healing problems and adapted constraints, which allow for the treatment of most resectable extremity tumours, the concept warrants further evaluation in patients unfit for standard radiotherapy., (© 2021 Vlatko Potkrajcic, Frank Traub, Barbara Hermes, Marcus Scharpf, Jonas Kolbenschlag, Daniel Zips, Frank Paulsen, Franziska Eckert, published by Sciendo.)
- Published
- 2021
- Full Text
- View/download PDF
14. p53 isoforms differentially impact on the POLι dependent DNA damage tolerance pathway.
- Author
-
Guo Y, Rall-Scharpf M, Bourdon JC, Wiesmüller L, and Biber S
- Subjects
- DNA Replication, Humans, K562 Cells, Mitomycin pharmacology, Models, Biological, Proliferating Cell Nuclear Antigen metabolism, Protein Binding drug effects, Protein Isoforms chemistry, Protein Isoforms metabolism, Protein Multimerization, Recombination, Genetic genetics, Subcellular Fractions metabolism, Tumor Suppressor Protein p53 chemistry, Ubiquitination, DNA Polymerase iota, DNA Damage, DNA-Directed DNA Polymerase metabolism, Tumor Suppressor Protein p53 metabolism
- Abstract
The recently discovered p53-dependent DNA damage tolerance (DDT) pathway relies on its biochemical activities in DNA-binding, oligomerization, as well as complex formation with the translesion synthesis (TLS) polymerase iota (POLι). These p53-POLι complexes slow down nascent DNA synthesis for safe, homology-directed bypass of DNA replication barriers. In this study, we demonstrate that the alternative p53-isoforms p53β, p53γ, Δ40p53α, Δ133p53α, and Δ160p53α differentially affect this p53-POLι-dependent DDT pathway originally described for canonical p53α. We show that the C-terminal isoforms p53β and p53γ, comprising a truncated oligomerization domain (OD), bind PCNA. Conversely, N-terminally truncated isoforms have a reduced capacity to engage in this interaction. Regardless of the specific loss of biochemical activities required for this DDT pathway, all alternative isoforms were impaired in promoting POLι recruitment to PCNA in the chromatin and in decelerating DNA replication under conditions of enforced replication stress after Mitomycin C (MMC) treatment. Consistent with this, all alternative p53-isoforms no longer stimulated recombination, i.e., bypass of endogenous replication barriers. Different from the other isoforms, Δ133p53α and Δ160p53α caused a severe DNA replication problem, namely fork stalling even in untreated cells. Co-expression of each alternative p53-isoform together with p53α exacerbated the DDT pathway defects, unveiling impaired POLι recruitment and replication deceleration already under unperturbed conditions. Such an inhibitory effect on p53α was particularly pronounced in cells co-expressing Δ133p53α or Δ160p53α. Notably, this effect became evident after the expression of the isoforms in tumor cells, as well as after the knockdown of endogenous isoforms in human hematopoietic stem and progenitor cells. In summary, mimicking the situation found to be associated with many cancer types and stem cells, i.e., co-expression of alternative p53-isoforms with p53α, carved out interference with p53α functions in the p53-POLι-dependent DDT pathway., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
15. Sex-specific differences in DNA double-strand break repair of cycling human lymphocytes during aging.
- Author
-
Rall-Scharpf M, Friedl TWP, Biechonski S, Denkinger M, Milyavsky M, and Wiesmüller L
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Sex Factors, Young Adult, Aging physiology, DNA Breaks, Double-Stranded, DNA Repair physiology, Lymphocytes physiology
- Abstract
The gender gap in life expectancy and cancer incidence suggests differences in the aging process between the sexes. Genomic instability has been recognized as a key factor in aging, but little is known about sex-specific differences. Therefore, we analyzed DNA double-strand break (DSB) repair in cycling human peripheral blood lymphocytes (PBL) from male and female donors of different age. Reporter-based DSB repair analyses revealed differential regulation of pathway usage in PBL from male and female donors with age: Non-homologous end joining (NHEJ) was inversely regulated in men and women; the activity of pathways requiring end processing and strand annealing steps such as microhomology-mediated end joining (MMEJ) declined with age in women but not in men. Screening candidate proteins identified the NHEJ protein KU70 as well as the end resection regulatory factors ATM and BLM showing reduced expression during aging in women. Consistently, the regulatory factor BLM contributed to the MMEJ proficiency in young but not in old women as demonstrated by knockdown analysis. In conclusion, we show that DSB repair is subject to changes upon aging and age-related changes in DSB repair are distinct in men and women.
- Published
- 2021
- Full Text
- View/download PDF
16. MR Thermometry Data Correlate with Pathological Response for Soft Tissue Sarcoma of the Lower Extremity in a Single Center Analysis of Prospectively Registered Patients.
- Author
-
Unsoeld M, Lamprecht U, Traub F, Hermes B, Scharpf M, Potkrajcic V, Zips D, Paulsen F, and Eckert F
- Abstract
Background : There is a strong biologic rationale for using locoregional hyperthermia in soft tissue sarcoma and a randomized trial reported significant improvements with hyperthermia. The aim of this study was to describe the opportunities of magnetic resonance (MR)-based thermometry in a cohort of soft tissue sarcoma patients undergoing combined radiotherapy and locoregional hyperthermia. Patients and Methods : For eleven evaluable patients, tumor volume (V
Tu ) and a separate volume for temperature analysis with reliable temperature distribution (Vtherm ) were contoured for every hyperthermia treatment (103 therapies). Temperature data were recorded for all tumors and were correlated with clinical features and pathologic response data. Results : Of 48 patients with high-risk soft tissue sarcomas treated with radio(chemo)therapy and locoregional hyperthermia, MR thermometry was possible in 11 (23%) patients. For all patients, the temperature superseded by 90% of VTu (T90(VTu )) and T90 (Vtherm ) were in the range of 37-43 °C and 40-45 °C, respectively. Larger tumors tended to reach higher temperatures. For tumors showing a pathologic response in the resection specimen after preoperative treatment, temperature (T90 (Vtherm )) was significantly higher than in tumors without pathologic response. Conclusion : Lower extremity sarcomas undergoing preoperative treatment with locoregional hyperthermia are especially suitable for MR thermometry. MR thermometry is a promising non-invasive way for temperature measurement during locoregional hyperthermia, showing a positive dose-response relationship.- Published
- 2020
- Full Text
- View/download PDF
17. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
- Author
-
Reustle A, Di Marco M, Meyerhoff C, Nelde A, Walz JS, Winter S, Kandabarau S, Büttner F, Haag M, Backert L, Kowalewski DJ, Rausch S, Hennenlotter J, Stühler V, Scharpf M, Fend F, Stenzl A, Rammensee HG, Bedke J, Stevanović S, Schwab M, and Schaeffeler E
- Subjects
- Adult, Aged, Aged, 80 and over, Binding Sites, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell therapy, Cell Line, Tumor, Female, HLA Antigens chemistry, Humans, Hypoxia-Inducible Factor-Proline Dioxygenases chemistry, Hypoxia-Inducible Factor-Proline Dioxygenases immunology, Kidney metabolism, Kidney Neoplasms genetics, Kidney Neoplasms therapy, Ligands, Lymphocyte Activation, Male, Middle Aged, Mutation, Peptide Fragments immunology, Protein Binding, Transcriptome, Carcinoma, Renal Cell immunology, Genomics methods, HLA Antigens immunology, Immunotherapy methods, Kidney Neoplasms immunology
- Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is the dominant subtype of renal cancer. With currently available therapies, cure of advanced and metastatic ccRCC is achieved only in rare cases. Here, we developed a workflow integrating different -omics technologies to identify ccRCC-specific HLA-presented peptides as potential drug targets for ccRCC immunotherapy., Methods: We analyzed HLA-presented peptides by MS-based ligandomics of 55 ccRCC tumors (cohort 1), paired non-tumor renal tissues, and 158 benign tissues from other organs. Pathways enriched in ccRCC compared to its cell type of origin were identified by transcriptome and gene set enrichment analyses in 51 tumor tissues of the same cohort. To retrieve a list of candidate targets with involvement in ccRCC pathogenesis, ccRCC-specific pathway genes were intersected with the source genes of tumor-exclusive peptides. The candidates were validated in an independent cohort from The Cancer Genome Atlas (TCGA KIRC, n = 452). DNA methylation (TCGA KIRC, n = 273), somatic mutations (TCGA KIRC, n = 392), and gene ontology (GO) and correlations with tumor metabolites (cohort 1, n = 30) and immune-oncological markers (cohort 1, n = 37) were analyzed to characterize regulatory and functional involvements. CD8
+ T cell priming assays were used to identify immunogenic peptides. The candidate gene EGLN3 was functionally investigated in cell culture., Results: A total of 34,226 HLA class I- and 19,325 class II-presented peptides were identified in ccRCC tissue, of which 443 class I and 203 class II peptides were ccRCC-specific and presented in ≥ 3 tumors. One hundred eighty-five of the 499 corresponding source genes were involved in pathways activated by ccRCC tumors. After validation in the independent cohort from TCGA, 113 final candidate genes remained. Candidates were involved in extracellular matrix organization, hypoxic signaling, immune processes, and others. Nine of the 12 peptides assessed by immunogenicity analysis were able to activate naïve CD8+ T cells, including peptides derived from EGLN3. Functional analysis of EGLN3 revealed possible tumor-promoting functions., Conclusions: Integration of HLA ligandomics, transcriptomics, genetic, and epigenetic data leads to the identification of novel functionally relevant therapeutic targets for ccRCC immunotherapy. Validation of the identified targets is recommended to expand the treatment landscape of ccRCC.- Published
- 2020
- Full Text
- View/download PDF
18. Safety and effectiveness of a novel generator algorithm for bipolar vessel sealing: a randomised controlled chronic animal study.
- Author
-
Kraemer B, Tsaousidis C, Kruck S, Schenk M, Scharpf M, Kommoss S, Brucker S, Nuessle D, Enderle MD, and Biber U
- Subjects
- Animals, Female, Arteries surgery, Electrocoagulation, Ligation, Swine, Veins, Random Allocation, Algorithms, Electrosurgery methods, Nephrectomy methods, Splenectomy methods
- Abstract
Background: Electrosurgical vessel sealers are gradually replacing conventional techniques such as ligation and clipping. Algorithms that control electrosurgical units (ESU), known as modes, are important for applications in different surgical disciplines. This chronic porcine animal study aimed to evaluate the safety and effectiveness of the novel thermoSEAL electrosurgical vessel sealing mode (TSM). The BiClamp® mode (BCM) of the renowned VIO® 300 D ESU served as control. BCM has been widely available since 2002 and has since been successfully used in many surgical disciplines. The TSM, for the novel VIO® 3 ESU, was developed to reduce sealing time and/or thermal lateral spread adjacent to the seal while maintaining clinical success rates. The primary aim of this study was to investigate the long-term and intraoperative seal quality of TSM., Methods: The BiCision® device was used for vessel sealing with TSM and BCM in ten German Landrace pigs which underwent splenectomy and unilateral nephrectomy during the first intervention of the study. The seals were cut with the BiCision® knife. Ninety-nine arteries, veins and vascular bundles were chronically sealed for 5 or 21 days. Thereafter, during the second and terminal intervention of the study, 97 additional arteries and veins were sealed. The carotid arteries were used for histological evaluation of thermal spread., Results: After each survival period, no long-term complications occurred with either mode. The intraoperative seal failure rates, i.e. vessel leaking or residual blood flow after the first sealing activation, were 2% with TSM versus 6% with BCM (p = 0.28). The sealing time was significantly shorter with TSM (3.5 ± 0.69 s vs. 7.3 ± 1.3 s, p < 0.0001). The thermal spread and burst pressure of arteries sealed with both modes were similar (p = 0.18 and p = 0.61) and corresponded to the histological evaluation. The measured tissue sticking parameter was rare with both modes (p = 0.33). Tissue charring did not occur. Regarding the cut quality, 97% of the seals were severed in the first and 3% in the second attempt (both with TSM and BCM)., Conclusions: The novel TSM seals blood vessels twice as fast as the BCM while maintaining excellent tissue effect and clinical success rates., Trial Registration: Not applicable.
- Published
- 2019
- Full Text
- View/download PDF
19. Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation.
- Author
-
Neumann E, Klaiber P, Freitag K, Schwab M, Schaeffeler E, Hennenlotter J, Fend F, Kruck S, Scharpf M, Stenzl A, Bedke J, and Rausch S
- Subjects
- Adolescent, Adrenergic beta-Antagonists administration & dosage, Adult, Aged, Aged, 80 and over, Anticoagulants administration & dosage, Cell Cycle drug effects, Cell Proliferation drug effects, Diuretics administration & dosage, Female, Humans, Hypoglycemic Agents administration & dosage, Male, Middle Aged, Neoplasm Staging, Prognosis, Young Adult, Carcinoma, Renal Cell pathology, Carcinoma, Renal Cell surgery, Kidney Neoplasms pathology, Kidney Neoplasms surgery, Pharmaceutical Preparations administration & dosage
- Abstract
Introduction: Based on the observation of beneficial effects on cancer metabolism, microenvironment, or VEGF-signaling, several non-anticancer drugs have been discussed as useful in renal cell carcinoma (RCC). In the present study, we investigated the prognostic impact of concomitant medication in RCC and correlated comedication with cell-cycle and proliferation activity in corresponding surgical specimen., Methods: A total of 388 patients who underwent surgery for localized RCC were included. The individual medication was evaluated according to substance classes. Tissue microarrays from corresponding tumor specimen were immunohistochemically (IHC) stained for Cyclin D1 and Ki67 and semi-quantitatively evaluated. Uni- and multivariate analyses were used to compare survival outcomes. For the comparison of IHC expression according to medication subgroups, Kruskal-Wallis analysis was performed., Results: Median follow-up was 57.93 months (95% CI 53.27-69.43) and median OS accounted for 181.12 months (129.72-237.17). Univariate analysis identified pathological standard variables (T-stage > T2, Grading > G2, L1, N1, M1, sarcomatoid subtype, necrosis) as significant determinants of OS. Moreover, statin use (p = 0.009) and sartan use (p = 0.032) were significantly associated with improved OS. Multivariate analysis identified M1-stage (p < 0.001), statin and sartan use (p = 0.003 and p = 0.033, respectively) as independent prognosticators of survival. Expression of Ki67 was significantly reduced in patients with statin use (p = 0.013), while Cyclin D1 expression showed no correlation with comedication., Conclusions: Concomitant intake of statins and sartans identifies as an independent predictor of OS in RCC, and reduced Ki67 expression was significantly associated with statin use. Further evaluation of drug repurposing approaches with these substances in RCC appear warranted.
- Published
- 2019
- Full Text
- View/download PDF
20. Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma.
- Author
-
Büttner F, Winter S, Rausch S, Hennenlotter J, Kruck S, Stenzl A, Scharpf M, Fend F, Agaimy A, Hartmann A, Bedke J, Schwab M, and Schaeffeler E
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell mortality, Carcinoma, Renal Cell pathology, Cohort Studies, Female, Humans, Kidney Neoplasms mortality, Kidney Neoplasms pathology, Male, Middle Aged, Prognosis, Survival Rate, Treatment Outcome, Carcinoma, Renal Cell epidemiology, Kidney Neoplasms epidemiology
- Abstract
Background: Stratification of cancer patients to identify those with worse prognosis is increasingly important. Through in silico analyses, we recently developed a gene expression-based prognostic score (S3-score) for clear cell renal cell carcinoma (ccRCC), using the cell type-specific expression of 97 genes within the human nephron. Herein, we verified the score using whole-transcriptome data of independent cohorts and extend its application for patients with metastatic disease receiving tyrosine kinase inhibitor treatment. Finally, we sought to improve the signature for clinical application using qRT-PCR., Methods: A 97 gene-based S3-score (S3
97 ) was evaluated in a set of 52 primary non-metastatic and metastatic ccRCC patients as well as in 53 primary metastatic tumors of sunitinib-treated patients. Gene expression data of The Cancer Genome Atlas (n = 463) was used for platform transfer and development of a simplified qRT-PCR-based 15-gene S3-score (S315 ). This S315 -score was validated in 108 metastatic and non-metastatic ccRCC patients and ccRCC-derived metastases including in part several regions from one metastasis. Univariate and multivariate Cox regression stratified by T, N, M, and G were performed with cancer-specific and progression-free survival as primary endpoints., Results: The S397 -score was significantly associated with cancer-specific survival (CSS) in 52 ccRCC patients (HR 2.9, 95% Cl 1.0-8.0, PLog-rank = 3.3 × 10-2 ) as well as progression-free survival in sunitinib-treated patients (2.1, 1.1-4.2, PLog-rank = 2.2 × 10-2 ). The qRT-PCR based S315 -score performed similarly to the S397 -score, and was significantly associated with CSS in our extended cohort of 108 patients (5.0, 2.1-11.7, PLog-rank = 5.1 × 10-5 ) including metastatic (9.3, 1.8-50.0, PLog-rank = 2.3 × 10-3 ) and non-metastatic patients (4.4, 1.2-16.3, PLog-rank = 1.6 × 10-2 ), even in multivariate Cox regression, including clinicopathological parameters (7.3, 2.5-21.5, PWald = 3.3 × 10-4 ). Matched primary tumors and metastases revealed similar S315 -scores, thus allowing prediction of outcome from metastatic tissue. The molecular-based qRT-PCR S315 -score significantly improved prediction of CSS by the established clinicopathological-based SSIGN score (P = 1.6 × 10-3 )., Conclusion: The S3-score offers a new clinical avenue for ccRCC risk stratification in the non-metastatic, metastatic, and sunitinib-treated setting.- Published
- 2018
- Full Text
- View/download PDF
21. Attenuated DNA damage responses and increased apoptosis characterize human hematopoietic stem cells exposed to irradiation.
- Author
-
Biechonski S, Olender L, Zipin-Roitman A, Yassin M, Aqaqe N, Marcu-Malina V, Rall-Scharpf M, Trottier M, Meyn MS, Wiesmüller L, Beider K, Raz Y, Grisaru D, Nagler A, and Milyavsky M
- Subjects
- Cells, Cultured, Genomic Instability radiation effects, Hematopoietic Stem Cells cytology, Hematopoietic Stem Cells metabolism, Humans, Karyotype, Radiation, Ionizing, Apoptosis radiation effects, DNA Damage radiation effects, DNA Repair radiation effects, Hematopoietic Stem Cells radiation effects
- Abstract
Failure to precisely repair DNA damage in self-renewing Hematopoietic Stem and early Progenitor Cells (HSPCs) can disrupt normal hematopoiesis and promote leukemogenesis. Although HSPCs are widely considered a target of ionizing radiation (IR)-induced hematopoietic injury, definitive data regarding cell death, DNA repair, and genomic stability in these rare quiescent cells are scarce. We found that irradiated HSPCs, but not lineage-committed progenitors (CPs), undergo rapid ATM-dependent apoptosis, which is suppressed upon interaction with bone-marrow stroma cells. Using DNA repair reporters to quantify mutagenic Non-Homologous End Joining (NHEJ) processes, we found that HSPCs exhibit reduced NHEJ activities in comparison with CPs. HSPC-stroma interactions did not affect the NHEJ capacity of HSPCs, emphasizing its cell autonomous regulation. We noted diminished expression of multiple double strand break (DSB) repair transcripts along with more persistent 53BP1 foci in irradiated HSPCs in comparison with CPs, which can account for low NHEJ activity and its distinct control in HSPCs. Finally, we documented clonal chromosomal aberrations in 10% of IR-surviving HSPCs. Taken together, our results revealed potential mechanisms contributing to the inherent susceptibility of human HSPC to the cytotoxic and mutagenic effects of DNA damage.
- Published
- 2018
- Full Text
- View/download PDF
22. A prospective randomized experimental study to investigate the peritoneal adhesion formation after waterjet injection and argon plasma coagulation (HybridAPC) in a rat model.
- Author
-
Kraemer B, Scharpf M, Keckstein S, Dippon J, Tsaousidis C, Brunecker K, Enderle MD, Neugebauer A, Nuessle D, Fend F, Brucker S, Taran FA, Kommoss S, and Rothmund R
- Subjects
- Abdominal Wall pathology, Animals, Electrocoagulation adverse effects, Electrocoagulation methods, Female, Humans, Incidence, Injections, Peritoneal Diseases complications, Peritoneal Diseases pathology, Peritoneum pathology, Postoperative Complications pathology, Postoperative Period, Prospective Studies, Random Allocation, Rats, Rats, Wistar, Tissue Adhesions etiology, Tissue Adhesions pathology, Argon Plasma Coagulation adverse effects, Disease Models, Animal, Peritoneal Diseases etiology, Tissue Adhesions chemically induced
- Abstract
Background: This prospective, randomized, controlled, single-blinded study investigates the peritoneal adhesion formation of HybridAPC (waterjet elevation of the peritoneum with subsequent argon plasma coagulation) versus only waterjet (elevation with the same instrument, but without subsequent argon plasma coagulation) in a rat model (24 female Wistar rats)., Materials and Methods: Bilateral lesions were created on the abdominal wall with HybridAPC on one sidewall and waterjet elevation on the other sidewall of the peritoneum in a standard fashion. After 10 days, the rats were euthanized to evaluate the peritoneal trauma sites., Main Outcome Measure(s): Adhesion incidence, quantity, and quality were scored 10 days postoperatively and studied histopathologically., Result(s): Incidence of adhesion formation was 2.3% for HybridAPC; no adhesions occurred for peritoneal elevation with saline (p = 1.00). Histologic evaluation revealed no acute inflammation in both groups. An overall moderate degree of granulation tissue formation and myonecrosis was observed in the HybridAPC group, whereas no chronic inflammation and myonecrosis occurred after elevation without thermal ablation (p < 0.0001)., Conclusion(s): This study investigates the effect of waterjet elevation of the peritoneum with and without subsequent thermal ablation on adhesion formation in a rat model for the first time. Peritoneal waterjet elevation with saline does not provide any risk of adhesion formation. Thermal coagulation with APC after waterjet elevation of the peritoneum creates advantageous peritoneal conditions due to a permanent moist tissue surface and the cooling effect of the injected solution, resulting in no significant difference in adhesion formation compared to peritoneal elevation without thermal ablation. HybridAPC can thus be regarded as a beneficial coagulation method with only minor adhesion formation due to positive tissue effects of the combined waterjet.
- Published
- 2018
- Full Text
- View/download PDF
23. Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes.
- Author
-
Winter S, Fisel P, Büttner F, Rausch S, D'Amico D, Hennenlotter J, Kruck S, Nies AT, Stenzl A, Junker K, Scharpf M, Hofmann U, van der Kuip H, Fend F, Ott G, Agaimy A, Hartmann A, Bedke J, Schwab M, and Schaeffeler E
- Subjects
- Adult, Aged, Aged, 80 and over, Cell Line, Tumor, Cohort Studies, Epigenesis, Genetic drug effects, Female, Gene Expression Regulation, Neoplastic drug effects, Genome, Human, Humans, Male, Middle Aged, Neoplasm Metastasis, Promoter Regions, Genetic, RNA, Messenger genetics, RNA, Messenger metabolism, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell pathology, DNA Methylation genetics, Kidney Neoplasms genetics, Kidney Neoplasms pathology, Pharmacogenetics
- Abstract
Current therapies for metastatic clear cell renal cell carcinoma (ccRCC) show limited efficacy. Drug efficacy, typically investigated in preclinical cell line models during drug development, is influenced by pharmacogenes involved in targeting and disposition of drugs. Here we show through genome-wide DNA methylation profiling, that methylation patterns are concordant between primary ccRCC and macro-metastases irrespective of metastatic sites (rs ≥ 0.92). However, 195,038 (41%) of all investigated CpG sites, including sites within pharmacogenes, were differentially methylated (adjusted P < 0.05) in five established RCC cell lines compared to primary tumors, resulting in altered transcriptional expression. Exemplarily, gene-specific analyses of DNA methylation, mRNA and protein expression demonstrate lack of expression of the clinically important drug transporter OCT2 (encoded by SLC22A2) in cell lines due to hypermethylation compared to tumors or metastases. Our findings provide evidence that RCC cell lines are of limited benefit for prediction of drug effects due to epigenetic alterations. Similar epigenetic landscape of ccRCC-metastases and tumors opens new avenue for future therapeutic strategies.
- Published
- 2016
- Full Text
- View/download PDF
24. Oncologic Impact of Renal Tissue Adjacent to Renal Cell Carcinoma.
- Author
-
Aufderklamm S, Hennenlotter J, Todenhöfer T, Senghaas N, Scharpf M, Gakis G, Rausch S, Mischinger J, Bier S, Stenzl A, Schwentner C, and Bedke J
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Margins of Excision, Middle Aged, Neoplasm Recurrence, Local etiology, Carcinoma, Renal Cell surgery, Kidney Neoplasms surgery, Nephrons surgery
- Abstract
Aim: The aim of the study was to investigate the clinical impact of the surgical margin width after nephron-sparing surgery (NSS) on the oncological course of renal cell carcinoma (RCC)., Patients and Methods: The study comprised of 126 RCC patients with NSS between 2002 and 2009. Inclusion criteria were negative resection margins and a tumor diameter of ≤100 mm with the possibility of a complete circumferential histopathological reevaluation. The minimal benign margin width was correlated to the patients' clinical course., Results: Median safety margin width was revealed to be 1 mm. Nine of 126 patients (7.1%) developed recurrent disease (five local, four distant). All patients with local recurrence had safety margins ≤1 mm, whereas out of 49 patients with a margin >1 mm no one developed local recurrence (p=0.0245). Safety margin ≤1 mm showed associations with increased risk for overall recurrence in univariate and multivariate analysis (p=0.0531 and 0.0539, respectively)., Conclusion: Tumor adjacent renal parenchyma may have oncological relevance, corroborating the need for further molecular investigation of tumor-adjacent tissue in RCC., (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2016
25. Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma.
- Author
-
Rausch S, Hennenlotter J, Scharpf M, Teepe K, Kühs U, Aufderklamm S, Bier S, Mischinger J, Gakis G, Stenzl A, Schwentner C, and Todenhöfer T
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor genetics, Carcinoma in Situ genetics, Carcinoma in Situ pathology, Case-Control Studies, Female, Follow-Up Studies, High-Throughput Nucleotide Sequencing, Humans, Immunoenzyme Techniques, Male, Middle Aged, Neoplasm Grading, Neoplasm Invasiveness, Neoplasm Proteins genetics, Neoplasm Staging, Prognosis, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology, Survival Rate, Urologic Neoplasms genetics, Urologic Neoplasms pathology, Urothelium pathology, Biomarkers, Tumor metabolism, Carcinoma in Situ metabolism, Neoplasm Proteins metabolism, Prostatic Neoplasms metabolism, Urologic Neoplasms metabolism, Urothelium metabolism
- Abstract
Purpose: To determine the expression patterns of the proliferation marker prostate tumor overexpressed 1 (PTOV1) in invasive urothelial cancer (UC)., Methods: Corresponding UC and benign samples from paraffin-embedded tissue of 102 patients treated with cystectomy for invasive UC were immunohistochemically (IHC) assessed for PTOV1. Expression was evaluated gradually separated for cytoplasmic and nuclear staining. Results were correlated to histological and clinical data. To correlate PTOV1 expression with molecular subtypes of UC, analysis of PTOV1 RNA expression data of the Cancer Genome Atlas UC cohort was performed., Results: PTOV1 expression was present in UC and benign urothelium, whereby nuclear staining was significantly more frequent in UC tissue (p = 0.0004). Lower cytoplasmic expression was significantly associated with pathological stage >pT2 (p = 0.0014) and grade ≥G3 (p = 0.0041), respectively. IHC expression patterns did not show correlation to survival data. PTOV1 RNA expression correlated with features of the luminal UC subtype., Conclusions: Subcellular distribution seems to be the most important feature of PTOV1 expression in UC. Nuclear localization of PTOV1 along with cytoplasmic decrease in PTOV1 expression was identified as putative surrogate for PTOV1-associated cellular proliferation and dedifferentiation in UC. The functional relevance as well as the potential role of PTOV1 as a biomarker in UC remains to be specified in future studies.
- Published
- 2016
- Full Text
- View/download PDF
26. A Prospective Randomized Experimental Study to Investigate the Eradication Rate of Endometriosis after Surgical Resection versus Aerosol Plasma Coagulation in a Rat Model.
- Author
-
Rothmund R, Scharpf M, Tsaousidis C, Planck C, Enderle MD, Neugebauer A, Kroeker K, Nuessle D, Fend F, Brucker S, and Kraemer B
- Subjects
- Abdominal Wall, Animals, Disease Models, Animal, Endometriosis pathology, Female, Prospective Studies, Random Allocation, Rats, Wistar, Treatment Outcome, Endometriosis surgery, Laser Coagulation methods
- Abstract
Purpose: To investigate the eradication rate of endometriosis after surgical resection (SR) vs. thermal ablation with aerosol plasma coagulation (AePC) in a rat model., Methods: In this prospective, randomized, controlled, single-blinded animal study endometriosis was induced on the abdominal wall of 34 female Wistar rats. After 14 days endometriosis was either removed by SR or ablated by AePC. 14 days later the rats were euthanized to evaluate the eradication rate histopathologically. Intervention times were recorded., Results: Eradication rate of endometriosis after 14 days did not significantly differ between AePC and SR (p=0.22). Intervention time per endometrial lesion was 22.1 s for AePC and 51.8 s for SR (p<0.0001)., Conclusions: This study compares the eradication rate of the new aerosol plasma coagulation device versus standard surgical resection of endometriosis in a rat model. Despite being a thermal method, AePC showed equality towards SR regarding eradication rate but with significantly shorter intervention time.
- Published
- 2016
- Full Text
- View/download PDF
27. Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis.
- Author
-
Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, and Kenner L
- Published
- 2015
- Full Text
- View/download PDF
28. MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma.
- Author
-
Fisel P, Stühler V, Bedke J, Winter S, Rausch S, Hennenlotter J, Nies AT, Stenzl A, Scharpf M, Fend F, Kruck S, Schwab M, and Schaeffeler E
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell mortality, Cell Line, Tumor, Disease Progression, Female, Humans, Male, Middle Aged, Prognosis, Promoter Regions, Genetic genetics, RNA, Messenger biosynthesis, Young Adult, Basigin metabolism, Biomarkers, Tumor genetics, Carcinoma, Renal Cell pathology, DNA Methylation genetics, Monocarboxylic Acid Transporters metabolism, Muscle Proteins metabolism
- Abstract
Unlabelled: Cluster of differentiation 147 (CD147/BSG) is a transmembrane glycoprotein mediating oncogenic processes partly through its role as binding partner for monocarboxylate transporter MCT4/SLC16A3. As demonstrated for MCT4, CD147 is proposed to be associated with progression in clear cell renal cell carcinoma (ccRCC). In this study, we evaluated the prognostic relevance of CD147 in comparison to MCT4/SLC16A3 expression and DNA methylation., Methods: CD147 protein expression was assessed in two independent ccRCC-cohorts (n = 186, n = 59) by immunohistochemical staining of tissue microarrays and subsequent manual as well as automated software-supported scoring (Tissue Studio, Definien sAG). Epigenetic regulation of CD147 was investigated using RNAseq and DNA methylation data of The Cancer Genome Atlas. These results were validated in our cohort. Relevance of prognostic models for cancer-specific survival, comprising CD147 and MCT4 expression or SLC16A3 DNA methylation, was compared using chi-square statistics., Results: CD147 protein expression generated with Tissue Studio correlated significantly with those from manual scoring (P < 0.0001, rS = 0.85), indicating feasibility of software-based evaluation exemplarily for the membrane protein CD147 in ccRCC. Association of CD147 expression with patient outcome differed between cohorts. DNA methylation in the CD147/BSG promoter was not associated with expression. Comparison of prognostic relevance of CD147/BSG and MCT4/SLC16A3, showed higher significance for MCT4 expression and superior prognostic power for DNA methylation at specific CpG-sites in the SLC16A3 promoter (e.g. CD147 protein: P = 0.7780,Harrell's c-index = 53.7% vs. DNA methylation: P = 0.0076, Harrell's c-index = 80.0%)., Conclusions: Prognostic significance of CD147 protein expression could not surpass that of MCT4, especially of SLC16A3 DNA methylation, corroborating the role of MCT4 as prognostic biomarker for ccRCC.
- Published
- 2015
- Full Text
- View/download PDF
29. STAT3 regulated ARF expression suppresses prostate cancer metastasis.
- Author
-
Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, and Kenner L
- Subjects
- Animals, Cell Line, Disease Progression, Genes, p16, Humans, Interleukin-6 genetics, Male, Mice, Mice, Transgenic, Neoplasms, Experimental, PTEN Phosphohydrolase genetics, Proto-Oncogene Proteins c-mdm2 metabolism, STAT3 Transcription Factor genetics, Tumor Suppressor Protein p53 metabolism, Cyclin-Dependent Kinase Inhibitor p16 metabolism, Interleukin-6 metabolism, Prostatic Neoplasms metabolism, STAT3 Transcription Factor metabolism
- Abstract
Prostate cancer (PCa) is the most prevalent cancer in men. Hyperactive STAT3 is thought to be oncogenic in PCa. However, targeting of the IL-6/STAT3 axis in PCa patients has failed to provide therapeutic benefit. Here we show that genetic inactivation of Stat3 or IL-6 signalling in a Pten-deficient PCa mouse model accelerates cancer progression leading to metastasis. Mechanistically, we identify p19(ARF) as a direct Stat3 target. Loss of Stat3 signalling disrupts the ARF-Mdm2-p53 tumour suppressor axis bypassing senescence. Strikingly, we also identify STAT3 and CDKN2A mutations in primary human PCa. STAT3 and CDKN2A deletions co-occurred with high frequency in PCa metastases. In accordance, loss of STAT3 and p14(ARF) expression in patient tumours correlates with increased risk of disease recurrence and metastatic PCa. Thus, STAT3 and ARF may be prognostic markers to stratify high from low risk PCa patients. Our findings challenge the current discussion on therapeutic benefit or risk of IL-6/STAT3 inhibition.
- Published
- 2015
- Full Text
- View/download PDF
30. Real-time tissue differentiation based on optical emission spectroscopy for guided electrosurgical tumor resection.
- Author
-
Spether D, Scharpf M, Hennenlotter J, Schwentner C, Neugebauer A, Nüßle D, Fischer K, Zappe H, Stenzl A, Fend F, Seifert A, and Enderle M
- Abstract
Complete surgical removal of cancer tissue with effective preservation of healthy tissue is one of the most important challenges in modern oncology. We present a method for real-time, in situ differentiation of tissue based on optical emission spectroscopy (OES) performed during electrosurgery not requiring any biomarkers, additional light sources or other excitation processes. The analysis of the optical emission spectra, enables the differentiation of healthy and tumorous tissue. By using multi-class support vector machine (SVM) algorithms, distinguishing between tumor types also seems to be possible. Due to its fast reaction time (0.05s) the method can be used for real-time navigation helping the surgeon achieve complete resection. The system's easy realization has been proven by successful integration in a commercial electro surgical unit (ESU). In a first step the method was verified by using ex vivo tissue samples. The histological analysis confirmed, 95% of correctly classified tissue types.
- Published
- 2015
- Full Text
- View/download PDF
31. Randomized experimental study to investigate the peritoneal adhesion formation of conventional monopolar contact coagulation versus noncontact argon plasma coagulation in a rat model.
- Author
-
Kraemer B, Scharpf M, Planck C, Tsaousidis C, Enderle MD, Neugebauer A, Kroeker K, Fend F, Brucker S, and Rothmund R
- Subjects
- Animals, Electrocoagulation methods, Female, Granulation Tissue pathology, Necrosis, Peritoneal Diseases pathology, Rats, Wistar, Time Factors, Tissue Adhesions, Argon Plasma Coagulation adverse effects, Electrocoagulation adverse effects, Peritoneal Diseases etiology, Peritoneum surgery
- Abstract
Objective: To investigate peritoneal adhesion formation of monopolar contact coagulation (MCC) versus noncontact argon plasma coagulation (APC) in a rat model., Design: Randomized, controlled, single-blinded animal study., Setting: University laboratory., Animal(s): Sixteen female Wistar rats., Intervention(s): Bilateral lesions were created on the abdominal wall with MCC and APC in a standard fashion. After 10 days, the rats were euthanized to evaluate the peritoneal trauma sites., Main Outcome Measure(s): Adhesion incidence, quantity, and quality were scored 10 days postoperatively and studied histopathologically., Result(s): Average energy intake was 99.5 ± 7.39 J for APC and 95.7 ± 9.62 J for monopolar contact coagulation. Incidence of adhesion formation was 50.0% for noncontact APC and 85.4% for MCC. MCC induced significantly more vascular adhesions. Histological evaluation revealed no significant differences regarding average depth of lesions induced by APC and MCC. Both groups showed almost identical morphology of necrosis and granulation tissue formation., Conclusion(s): This study compares for the first time adhesion formation of MCC versus noncontact APC in a rat model. With a similar energy intake, contact coagulation induced a significantly higher rate of adhesion formation. APC-induced adhesions were significantly less vascularized compared with MCC adhesions. Besides the thermal effects of both coagulation methods, the direct mechanical contact of the MCC electrode with the highly sensitive peritoneum is thus determined to be a pivotal additional stimulus for adhesion formation., (Copyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
32. The tissue effect of argon-plasma coagulation with prior submucosal injection (Hybrid-APC) versus standard APC: A randomized ex-vivo study.
- Author
-
Manner H, Neugebauer A, Scharpf M, Braun K, May A, Ell C, Fend F, and Enderle MD
- Abstract
Background: Thermal ablation for Barrett's oesophagus has widely been established in gastrointestinal endoscopy during the last decade. The mainly used methods of radiofrequency ablation (RFA) and argon-plasma coagulation (APC) carry a relevant risk of stricture formation of up to 5-15%. Newer ablation techniques that are able to overcome this disadvantage would therefore be desirable. The aim of the present study was to compare the depth of tissue injury of the new method of Hybrid-APC versus standard APC within a randomized study in a porcine oesophagus model., Methods: Using a total of eight explanted pig oesophagi, 48 oesophageal areas were ablated either by standard or Hybrid-APC (APC with prior submucosal fluid injection) using power settings of 50 and 70 W. The depth of tissue injury to the oesophageal wall was analysed macroscopically and histopathologically., Results: Using 50 W, mean coagulation depth was 937 ± 469 µm during standard APC, and 477 ± 271 µm during Hybrid-APC (p = 0.064). Using 70 W, coagulation depth was 1096 ± 320 µm (standard APC) and 468 ± 136 µm (Hybrid-APC; p = 0.003). During all settings, damage to the muscularis mucosae was observed. Using standard APC, damage to the submucosal layer was observed in 4/6 (50 W) and 6/6 cases (70 W). During Hybrid-APC, coagulation of the submucosal layer occurred in 2/6 (50 W) and 1/6 cases (70 W). The proper muscle layer was only damaged during conventional APC (50 W: 1/6; 70 W: 3/6)., Limitations: Ex-vivo animal study with limited number of cases., Conclusions: Hybrid-APC reduces coagulation depth by half in comparison with standard APC, with no thermal injury to the proper muscle layer. It may therefore lead to a lower rate of stricture formation during clinical application.
- Published
- 2014
- Full Text
- View/download PDF
33. A comparison of internally water-perfused and cryogenically cooled monopolar and bipolar radiofrequency applicators in ex vivo liver samples.
- Author
-
Rempp H, Mezger D, Voigtlaender M, Scharpf M, Hoffmann R, Pereira PL, Enderle MD, Claussen CD, and Clasen S
- Subjects
- Animals, Cattle, Cold Temperature, Equipment Design, Equipment Failure Analysis, In Vitro Techniques, Liver anatomy & histology, Water, Catheter Ablation instrumentation, Hepatectomy instrumentation, Liver surgery, Transducers
- Abstract
Rationale and Objectives: To evaluate the ex vivo ablation zones created in hepatic tissue using monopolar and bipolar gas- and water-cooled radiofrequency (RF) applicators., Materials and Methods: RF ablations were performed on ex vivo bovine liver tissue using closed circuit water-cooled and closed circuit cryogenically cooled (via CO₂ enthalpy) 15-ga linear-needle applicators. Both monopolar and bipolar electrode applicators were used, with the electric current administered ranging in 50-mA increments from 1100 to 1300 mA for the monopolar case, and from 500 to 700 mA for the bipolar case. Total ablation time was 15 minutes. Six tissue samples were ablated per setting. The ablated volumes were assumed to have a three-dimensional ellipsoid shape, with one long major axis and two smaller minor axes. Gross histology was used to measure the dimensions of the ablated regions to quantify the ablated volume, the dimensions of the axis, and the ratio between the long axis and the smallest minor axis, which was termed the ellipticity index., Results: The gas-cooled monopolar applicator achieved the largest short-axis ablation diameter (4.05 ± 0.4 cm), followed by the water-cooled monopolar applicator (3.18 ± 0.29 cm). With the bipolar applicator, the gas-cooled applicators also achieved larger short-axis ablation diameters (3.02 ± 0.15 cm) than the water-cooled applicators (2.72 ± 0.29 cm). The gas-cooled monopolar applicator also provided the largest ablation volume (42.7 ± 10.7 mL) and the most spherically shaped lesions (ellipticity index: 1.21 ± 0.10). Lesion size increased with injected current up to a threshold current of 1200/1250 mA (monopolar water-/gas-cooled) and 600/650 mA (bipolar water-/gas-cooled), but dropped at greater values., Conclusions: Gas-cooled monopolar applicators were superior to the other tested applicators in terms of both volume and sphericity of the ablation zone., (Copyright © 2014 AUR. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
34. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
- Author
-
Fisel P, Kruck S, Winter S, Bedke J, Hennenlotter J, Nies AT, Scharpf M, Fend F, Stenzl A, Schwab M, and Schaeffeler E
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Carcinoma, Renal Cell mortality, Carcinoma, Renal Cell secondary, Case-Control Studies, Epigenomics, Female, Follow-Up Studies, Humans, Immunoenzyme Techniques, Kidney Neoplasms mortality, Kidney Neoplasms pathology, Male, Middle Aged, Muscle Proteins genetics, Neoplasm Metastasis, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Rate, Symporters, Young Adult, Carcinoma, Renal Cell genetics, DNA Methylation, Gene Expression Regulation, Neoplastic, Kidney Neoplasms genetics, Monocarboxylic Acid Transporters genetics, Monocarboxylic Acid Transporters metabolism, Muscle Proteins metabolism, Promoter Regions, Genetic genetics
- Abstract
Purpose: The monocarboxylate transporter 4 (MCT4) is a metabolic target in tumor biology because it mediates lactate transport across membranes resulting in antiapoptotic effects. Cell experiments support the importance of MCT4 in clear cell renal cell carcinoma (ccRCC). In this study, we assessed the prognostic potential of MCT4 expression in ccRCC and its epigenetic regulation by DNA methylation as novel predictive marker for patient outcome using independent ccRCC cohorts., Experimental Design: MCT4 protein expression was quantified in 207 ccRCC and corresponding nontumor tissues. Data of an independent ccRCC cohort from The Cancer Genome Atlas (TCGA) were analyzed on MCT4 mRNA (n = 482) and DNA methylation (n = 283) level. The findings on MCT4 expression and DNA methylation in the SLC16A3 promoter were validated in a third cohort (n = 64). Promoter activity assays were conducted in four RCC cell lines., Results: MCT4 protein expression was upregulated (P < 0.0001) in ccRCC and showed significant association with cancer-related death. Upregulation of MCT4 mRNA expression (P < 0.00001) was confirmed in the TCGA cohort. Single CpG sites correlated inversely with mRNA expression and were associated with overall survival in Kaplan-Meier analyses [HR = 0.39; 95% confidence interval (CI), 0.24-0.64; P[log-rank] = 1.23e(-04)]. Promoter activity studies confirmed MCT4 regulation by DNA methylation. The significant correlation between MCT4 protein and gene expression or DNA methylation at single CpG sites was validated in a third cohort. Again, higher methylation at individual CpG sites was associated with prolonged survival [HR = 0.05; 95% CI, 0.01-0.40; P[log-rank] = 6.91e(-05)]., Conclusion: We identified SLC16A3 promoter DNA methylation as a novel epigenetic mechanism for MCT4 regulation in ccRCC with first evidence of a biological rationale for prognosis and clinical outcome., (©2013 AACR.)
- Published
- 2013
- Full Text
- View/download PDF
35. Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma.
- Author
-
Kruck S, Eyrich C, Scharpf M, Sievert KD, Fend F, Stenzl A, and Bedke J
- Subjects
- Cell Membrane metabolism, Cytoplasm metabolism, Disease-Free Survival, Female, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Kidney metabolism, Kidney pathology, Male, Middle Aged, Multivariate Analysis, Prognosis, Proportional Hazards Models, Carcinoma, Renal Cell metabolism, Carcinoma, Renal Cell pathology, Kidney Neoplasms metabolism, Kidney Neoplasms pathology, Wnt1 Protein metabolism, beta Catenin metabolism
- Abstract
In renal cell carcinoma (RCC), single members of the Wnt/β-catenin signaling cascade were recently identified to contribute to cancer progression. However, the role of Wnt1, one of the key ligands in β-catenin regulation, is currently unknown in RCC. Therefore, alterations of the Wnt1/β-catenin axis in clear cell RCC (ccRCC) were examined with regard to clinicopathology, overall survival (OS) and cancer specific survival (CSS). Corresponding ccRCCs and benign renal tissue were analyzed in 278 patients for Wnt1 and β-catenin expression by immunohistochemistry in tissue microarrays. Expression scores, including intensity and percentage of stained cells, were compared between normal kidney and ccRCCs. Data was categorized according to mean expression scores and correlated to tumor and patients' characteristics. Survival was analyzed according to the Kaplan-Meier and log-rank test. Univariable and multivariable Cox proportional hazard regression models were used to explore the independent prognostic value of Wnt1 and β-catenin. In ccRCCs, high Wnt1 was associated with increased tumor diameter, stage and vascular invasion (p ≤ 0.02). High membranous β-catenin was associated with advanced stage, vascular invasion and tumor necrosis (p ≤ 0.01). Higher diameter, stage, node involvement, grade, vascular invasion and sarcomatoid differentiation (p ≤ 0.01) were found in patients with high cytoplasmic β-catenin. Patients with a high cytoplasmic β-catenin had a significantly reduced OS (hazard ratio (HR) 1.75) and CSS (HR 2.26), which was not independently associated with OS and CSS after adjustment in the multivariable model. Increased ccRCC aggressiveness was reflected by an altered Wnt1/β-catenin signaling. Cytoplasmic β-catenin was identified as the most promising candidate associated with unfavorable clinicopathology and impaired survival. Nevertheless, the shift of membranous β-catenin to the cytoplasm with a subsequently increased nuclear expression, as shown for other malignancies, could not be demonstrated to be present in ccRCC.
- Published
- 2013
- Full Text
- View/download PDF
36. A rare case of synchronous renal cell carcinoma of the bladder presenting with gross hematuria.
- Author
-
Kruck S, Scharpf M, Stenzl A, and Bedke J
- Abstract
Unlabelled: A 57-year old man was referred to the Urology Department due to gross hematuria; abdominal ultrasound revealed an unspecific solid tumor of the left bladder wall. Ultrasound, transurethral resection of the bladder mass with subsequent histological analysis, thoracic and abdominal computed tomography-scan and brain magnetic resonance imaging were performed. He was diagnosed with a bladder metastasis of clear cell renal cell carcinoma (RCC) with concomitant bone, pulmonary, and cerebral metastatic disease of a primary RCC of the right kidney., Management: Transurethral resection of the bladder mass, cerebral and bone radiotherapy, removal of the primary tumor, targeted systemic therapy with mTOR followed by tyrosine kinase inhibition.
- Published
- 2013
- Full Text
- View/download PDF
37. Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer.
- Author
-
Heni M, Hennenlotter J, Scharpf M, Lutz SZ, Schwentner C, Todenhöfer T, Schilling D, Kühs U, Gerber V, Machicao F, Staiger H, Häring HU, and Stenzl A
- Subjects
- Aged, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Diabetes Mellitus, Type 2 genetics, Diabetes Mellitus, Type 2 metabolism, Gene Expression Regulation, Neoplastic, Humans, Insulin Receptor Substrate Proteins metabolism, Male, Middle Aged, Prostatectomy, Prostatic Hyperplasia metabolism, Prostatic Hyperplasia surgery, Prostatic Neoplasms metabolism, Prostatic Neoplasms surgery, Receptor, IGF Type 1 genetics, Receptor, IGF Type 1 metabolism, Receptor, Insulin metabolism, Insulin Receptor Substrate Proteins genetics, Prostate metabolism, Prostatic Hyperplasia genetics, Prostatic Neoplasms genetics, Receptor, Insulin genetics
- Abstract
Aims/hypothesis: In different cancers types, insulin receptor isoform composition or insulin receptor substrate (IRS) isoforms are different to healthy tissue. This may be a molecular link to increased cancer risk in diabetes and obesity. Since this is yet unclear for prostate cancer, we investigated IR isoform composition and IRS balance in prostate cancer compared to benign and tumor adjacent benign prostate tissue and brought this into relation to cell proliferation., Methods: We studied 23 benign prostate samples from radical cystectomy or benign prostatic hyperplasia surgery, 30 samples from benign tissue directly adjacent to prostate cancer foci and 35 cancer samples from different patients. RNA expression levels for insulin receptor isoforms A and B, IRS-1, IRS-2, and IGF-1 receptor were assessed by quantitative real-time RT-PCR. In addition, RNA- and protein expression of the cell cycle regulator p27(Kip1) was quantified by real-time RT-PCR and immunohistochemistry., Results: Insulin receptor isoform A to B ratio was significantly higher in cancer as well as in tumor adjacent benign prostate tissue compared to purely benign prostates (p<0.05). IRS-1 to IRS-2 ratios were lower in malignant than in benign prostatic tissue (p<0.05). These altered ratios both in cancer and adjacent tissue were significantly associated with reduced p27(Kip1) content (p<0.02). Interestingly, IGF-1 receptor levels were significantly lower in patients with type 2 diabetes (p = 0.0019)., Conclusions/interpretation: We found significant differences in the insulin signaling cascade between benign prostate tissue and prostate cancer. Histological benign tissue adjacent to cancer showed expression patterns similar to the malignancies. Our findings suggest a role of the insulin signaling pathway in prostate cancer and surrounding tissue and can hence be relevant for both novel diagnostic and therapeutic approaches in this malignancy.
- Published
- 2012
- Full Text
- View/download PDF
38. A prospective, randomized, experimental study to investigate the peritoneal adhesion formation of noncontact argon plasma coagulation in a rat model.
- Author
-
Kraemer B, Rothmund R, Fischer K, Scharpf M, Fend F, Smaxwil L, Enderle MD, Wallwiener D, and Neugebauer A
- Subjects
- Animals, Argon Plasma Coagulation adverse effects, Female, Peritoneal Diseases etiology, Prospective Studies, Random Allocation, Rats, Rats, Wistar, Tissue Adhesions etiology, Tissue Adhesions pathology, Argon Plasma Coagulation methods, Disease Models, Animal, Peritoneal Diseases pathology
- Abstract
Objective: To investigate the peritoneal adhesion formation of two pulsed noncontact argon plasma coagulation (APC) modes in a rat model., Design: Prospective, randomized, controlled, and blinded study., Setting: Laboratory facilities of a university department of obstetrics and gynecology., Animal(s): Ten female Wistar rats., Intervention(s): Bilateral lesions were created on the abdominal wall with low and high APC energy in a standard fashion. After 10 days the rats were killed to evaluate the peritoneal trauma sites., Main Outcome Measure(s): Adhesion incidence, quantity, and quality were scored 10 days after surgery and studied by histopathologic analysis., Result(s): The area of coagulation was 30 ± 8.4 mm(2) in the case of high APC energy and 12 ± 5.6 mm(2) (low APC energy). Macroscopic thermal damage of the peritoneum is significantly higher when applying high APC energy. Adhesions due to APC with high energy occurred in 64% and with low energy in 6% of cases. High energy results mainly in dense adhesions. The lesions in the high-energy group showed intense granulation tissue formation with centrally located myocyte necrosis with intense neutrophilic inflammation., Conclusion(s): This study describes for the first time that different noncontact APC energy settings induce peritoneal adhesions in a reproducible rat model. Higher energy produced significantly deeper tissue defects and adhesions of higher grade. A plasma coagulation system that develops fewer adhesions can be achieved by lower temperature and a more homogeneous application and if the application area desiccates more slowly., (Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.